Todos os estudos
RecrutamentoFarmacologia Humana (Fase I) - Primeira administração em humanosIntervencionista

First-in-man clinical trial to assess safety and tolerability of CEB-01 PLGA membrane in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma after surgery

This study is testing a new treatment called CEB-01 PLGA membrane for a type of cancer known as retroperitoneal soft tissue sarcoma. This is a rare cancer that affects soft tissues deep inside the body, and this study is specifically for patients where the cancer has returned or spread nearby after they’ve had surgery. Because this is the very first time this treatment is being given to people, the main goal is to find out if it's safe to use and how well patients' bodies cope with it. It's an early-stage study, meaning researchers are taking the first steps to understand this new approach before looking at whether it can cure the cancer.

Em resumo

Status
Recrutamento
Fase
Farmacologia Humana (Fase I) - Primeira administração em humanos
Patrocinador
Cebiotex S.L.
Meta de inscrição
21
Iniciar
20 Ago 2024

Sobre o que é este estudo?

This study is an important first step in testing a new treatment for a type of cancer called retroperitoneal soft tissue sarcoma. This cancer affects soft tissues – like fat, muscle, or blood vessels – deep inside your tummy area (retroperitoneal means behind the lining of your abdomen). It's a complicated cancer, and sometimes even after surgery to remove it, it can come back or grow nearby.

The new treatment being tested is a special patch or film, called CEB-01 PLGA membrane. Doctors are trying to see if placing this membrane in the body could help patients. Because this is the very first time this membrane is being given to humans, the main goal is to check its safety and see how well people's bodies tolerate it. This helps doctors learn the best way to use it and if it’s safe enough to study further.

Finding new ways to treat this type of soft tissue sarcoma is really important for patients. Even though this study is focused on safety, it's a crucial part of developing potential future treatments that could make a real difference. If this membrane proves to be safe, it could lead to more studies to see if it can help stop the cancer from coming back or spreading.

Pontos principais

  • This study is testing a new membrane treatment (CEB-01 PLGA) for retroperitoneal soft tissue sarcoma.
  • It's for patients whose cancer has returned or spread nearby after previous surgery.
  • The main aim is to assess the safety and how well people tolerate this new treatment.
  • This is a 'first-in-human' study, meaning it's the first time people are receiving this specific treatment.
  • It’s an early-stage study to gather important safety information for future research.

Quem pode ser elegível?

This study is for adults aged 18 and over. Both men and women can take part. To be suitable, you would need to have been diagnosed with retroperitoneal soft tissue sarcoma that has either come back or grown locally after you've already had an operation to remove it.

There might be other specific health requirements or conditions that mean you can or cannot join the study. These are put in place to ensure your safety and that the study results are clear.

It's very important to talk to your doctor or the study team to find out if this study is right for you. They can review your full medical history and explain all the detailed requirements.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você tem 18 anos ou mais?
  2. Have you been diagnosed with retroperitoneal soft tissue sarcoma?
  3. Has your cancer come back or spread locally after previous surgery?
  4. Are you able to attend regular hospital appointments and follow-up checks?
  5. Are you willing to discuss your full medical history with the study team?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part in this study, you would first have a number of checks to make sure you are suitable. Once enrolled, you would receive the CEB-01 PLGA membrane, likely during surgery. After this, you would have regular appointments at the hospital. These appointments are important for the medical team to monitor your health, check for any side effects from the treatment, and see how your body is responding.

These visits might include physical examinations, blood tests, and scans. The study team will explain exactly how many visits you would need, what each visit involves, and for how long you would be followed up. You would have a clear schedule, and all your questions would be answered before you start.

Riscos e benefícios potenciais

Taking part in any medical study carries potential benefits and risks. For this study, a potential benefit is receiving a brand new treatment approach that might help manage your cancer, although the main goal at this early stage is to assess safety, not to cure the disease. However, there are also potential risks, including side effects from the new membrane or from the procedures involved. The doctors and nurses will carefully monitor you for any problems. You will be fully informed about all known risks before you decide to join, and you have the right to withdraw from the study at any time, for any reason, without it affecting your usual care.

Localizações (1)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    Espanha

Perguntas frequentes

What is retroperitoneal soft tissue sarcoma?

It's a rare cancer that develops in the soft tissues (like muscle, fat, or blood vessels) located deep inside your abdomen, behind where most of your tummy organs are.

What is the CEB-01 PLGA membrane?

It's a new type of special patch or film that doctors are testing as a treatment. In this very first study, they want to find out if it is safe for people to use.

What does 'first-in-man' mean?

It means this is the very first time this treatment is being given to humans. It's an early safety check before it can be studied further to see if it treats cancer.

Will this treatment cure my cancer?

The main goal of this very early study is to check if the new treatment is safe and tolerable. It's not designed to look at whether it can cure the cancer at this stage.

Posso sair do estudo se mudar de ideia?

Yes, absolutely. You can decide to leave the study at any point, for any reason. Your medical care will not be affected if you choose to stop participating.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "First-in-man clinical trial to assess safety and tolerabilit…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.